Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy - PubMed (original) (raw)
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
E M Velazquez et al. Metabolism. 1994 May.
Abstract
Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1.5 g/d for 8 weeks, and were then restudied. None of the women had normal menstrual cycles, 100% had multiple subcapsular follicules by pelvic ultrasound, 90% were hirsute, and 85% had high free testosterone. Comparing post-Metformin versus baseline levels, the Quetelet Index (QI) decreased 1.5% (P = .04) and the waist to hip ratio (WHR) decreased 2.8% (P = .003). After covariance adjusting for changes in the QI and WHR, on Metformin the area under the insulin curve (IA) during oral glucose tolerance testing decreased 35% (P = .04), and the insulin area to glucose area ratio decreased 31% (P = .03). On Metformin, covariance-adjusted systolic blood pressure (SBP) decreased (P = .04) and apo A-1 increased (P = .05). On Metformin, with improvement in insulin sensitivity, there were sharp reductions in covariance-adjusted luteinizing hormone ([LH] P = .0007), total testosterone ([T] P = .0004), free T (P = .0001), androstenedione (P = .002), dehydroepiandrosterone sulfate ([DHEAS] P = .006), and the free androgen index ([FAI] P = .0005), with increments in follicle-stimulating hormone ([FSH] P = .04) and sex hormone-binding globulin ([SHBG] P = .04).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Pasquali R, et al. J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74. doi: 10.1210/jcem.85.8.6738. J Clin Endocrinol Metab. 2000. PMID: 10946879 Clinical Trial. - Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Kolodziejczyk B, et al. Fertil Steril. 2000 Jun;73(6):1149-54. doi: 10.1016/s0015-0282(00)00501-x. Fertil Steril. 2000. PMID: 10856473 Clinical Trial. - The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
Unlühizarci K, Keleştimur F, Bayram F, Sahin Y, Tutuş A. Unlühizarci K, et al. Clin Endocrinol (Oxf). 1999 Aug;51(2):231-6. doi: 10.1046/j.1365-2265.1999.00786.x. Clin Endocrinol (Oxf). 1999. PMID: 10468995 - Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Patel R, Shah G. Patel R, et al. Curr Med Res Opin. 2017 Sep;33(9):1545-1557. doi: 10.1080/03007995.2017.1279597. Epub 2017 Feb 3. Curr Med Res Opin. 2017. PMID: 28058854 Review. - Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Naderpoor N, et al. Hum Reprod Update. 2015 Sep-Oct;21(5):560-74. doi: 10.1093/humupd/dmv025. Epub 2015 Jun 9. Hum Reprod Update. 2015. PMID: 26060208 Review.
Cited by
- Polymorphisms of OCT1 and metformin effects in Iraqi women with polycystic ovary syndrome in Karbala city.
Kadhem AH, Gholizadeh A. Kadhem AH, et al. Int J Biochem Mol Biol. 2024 Jun 15;15(3):60-67. doi: 10.62347/XARB9847. eCollection 2024. Int J Biochem Mol Biol. 2024. PMID: 39021868 Free PMC article. - Evaluating the therapeutic potential of moxibustion on polycystic ovary syndrome: a rat model study on gut microbiota and metabolite interaction.
Lin Y, Zeng H, Lin J, Peng Y, Que X, Wang L, Chen L, Bai N. Lin Y, et al. Front Cell Infect Microbiol. 2024 Apr 11;14:1328741. doi: 10.3389/fcimb.2024.1328741. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38665877 Free PMC article. - The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.
Jensterle M, Ferjan S, Janez A. Jensterle M, et al. Front Endocrinol (Lausanne). 2024 Apr 11;15:1366940. doi: 10.3389/fendo.2024.1366940. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38665260 Free PMC article. - Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.
Ji S, Yang H, Ji Y, Wu W, Dong Y, Fu H, Tang N, Hou Z, Wang F. Ji S, et al. Reprod Sci. 2024 Jul;31(7):2049-2058. doi: 10.1007/s43032-024-01503-0. Epub 2024 Mar 5. Reprod Sci. 2024. PMID: 38441776 - The Comparative Effects of Myo-Inositol and Metformin Therapy on the Clinical and Biochemical Parameters of Women of Normal Weight Suffering from Polycystic Ovary Syndrome.
Gudović A, Bukumirić Z, Milincic M, Pupovac M, Andjić M, Ivanovic K, Spremović-Rađenović S. Gudović A, et al. Biomedicines. 2024 Feb 2;12(2):349. doi: 10.3390/biomedicines12020349. Biomedicines. 2024. PMID: 38397951 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous